Advanced prostate cancer: AUA/SUO guideline.

Guideline ID: 1891 Published: 2023

American Urological Association Education and Research, Inc. (AUA) | Society of Urologic Oncology (SUO)

Lowrance W, Breau R, Chou R, et al. Advanced prostate cancer: AUA/SUO guideline. Linthicum (MD): American Urological Association Education and Research, Inc.; 2023. 53 p. [173 references]

View Original Guideline

Overview

Guideline Objective

To provide a rational basis for evidence-based treatment for advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to widespread metastatic disease

Note: This guideline does not cover local therapy (refer to the Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline or additional information). Furthermore, neuroendocrine tumors and small cell variants were considered outside the scope of this guideline.

Patient Population

Patients with advanced prostate cancer

Note: The patient population covered in this guideline is assumed to have already received local or pelvic therapy, including adjuvant and salvage therapy (i.e., exhaustion of local treatment options).

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Early evaluation and counseling
- Prognosis and treatment of biochemical recurrence without metastatic disease after exhaustion of local treatment options, metastatic hormone-sensitive, non-metastatic and metastatic castration-resistant prostate cancer
- Bone health and role of preventive treatments

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- The Original Guideline is also available from the *Journal of Urology*; 2023 Jun.
- Guideline Amendment Summary; 2023.
- American Urological Association Clinical Practice Guidelines Development; 2015.

Implementation Tools

- Advanced Prostate Cancer Algorithm; 2023.
- AUA Guidelines-At-A-Glance Mobile App is available for Android and iOS.

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

TRUST Scorecard

Composition of Guideline Development Group (GDG)

Multidisciplinary GDG Members	Yes
Methodologist Involvement	
Incorporation of Patient and Public Perspective	NOT AVAILABLE

Systematic Review of Evidence

Literature Search	NOT AVAILABLE
Study Selection	NOT AVAILABLE
Evidence Synthesis	NOT AVAILABLE

Foundations for Recommendations

Strength of Evidence Grade	NOT AVAILABLE
Description of Benefits and Harms of Recommendations	NOT AVAILABLE
Summary of Evidence Supporting Recommendations	NOT AVAILABLE
Strength of Recommendations Rating	NOT AVAILABLE
Clear Articulation of Recommendations	NOT AVAILABLE

Funding Source — Yes

Disclosure and Management of Financial Conflicts of Interests — NOT AVAILABLE

External Review — NOT AVAILABLE

Updating — NOT AVAILABLE

Copyright © 2025 ECRI